Review
Oncology
Aleix Prat, Aditya Bardia, Giuseppe Curigliano, M. Elizabeth H. Hammond, Sibylle Loibl, Sara M. Tolaney, Giuseppe Viale
Summary: ERBB2 is an important prognostic and predictive factor in breast cancer. However, tumors with low ERBB2 expression are currently classified as ERBB2-negative and ineligible for anti-ERBB2 therapies, even though they account for a significant percentage of breast cancer cases. This review highlights the potential therapeutic target of ERBB2-low tumors and the need for reevaluation of diagnostic and therapeutic paradigms.
Article
Biochemistry & Molecular Biology
Peeyush N. Goel, Hongtao Zhang, Ramachandran Murali, Cai Zheng, Mei Q. Ji, Angelica Patterson, Payal Grover, Mark Greene
Summary: Mutations in the EGFR gene are common in NSCLC, with the L858R mutation in Exon 21 being the most prevalent. While targeted therapies like monoclonal antibodies and TKIs have shown efficacy, resistance eventually develops due to mutations such as T790M and C797S. A third-generation TKI, AZD9291, has high affinity for these mutations, but recent research suggests the emergence of resistance due to the EGFR (C797S) mutation. Additionally, erbB2 amplification is another significant mechanism of resistance. A small kinase inhibitor, ER121, has been developed to target these mutations and has shown promising inhibitory activity in mutant EGFR and amplified ErbB2 cancers.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Article
Cell Biology
Yanli Bi, Longyuan Gong, Pengyuan Liu, Xiufang Xiong, Yongchao Zhao
Summary: This study reveals a novel mechanism in which nuclear ErbB2 represses the transcription of DEPTOR, leading to activation of the PI3K/AKT/mTOR pathway to inhibit autophagy.
CELL DEATH & DISEASE
(2021)
Article
Medicine, General & Internal
Marcela Carausu, Matthieu Carton, Veronique Dieras, Thierry Petit, Severine Guiu, Anthony Goncalves, Paule Augereau, Jean Marc Ferrero, Christelle Levy, Mony Ung, Isabelle Desmoulins, Marc Debled, Thomas Bachelot, Barbara Pistilli, Jean-Sebastien Frenel, Audrey Mailliez, Michael Chevrot, Luc Cabel
Summary: Evidence suggests that patients with HR+/ERBB2+ metastatic breast cancer have different clinical characteristics and outcomes. The association of HR status and first-line inclusion of ET with outcomes among patients with ERBB2+ MBC was evaluated. ET-containing first-line regimens may be associated with benefits in a subgroup of patients with HR+/ERBB2+ MBC.
Article
Chemistry, Physical
Ya-Ting Hsu, Li-Hsien Chen, Ya-Hui Liu, Shih-Kai Chu, Tsai-Yun Chen, Kuen-Jer Tsai, Meng-Ru Shen, Wentai Liu
Summary: This study demonstrates that electrical sympathetic neuromodulation (ESN) of the bone marrow can protect it from chemotherapy-induced injury and promote hematopoietic regeneration. ESN can mediate the production of several hematopoietic stem cell maintenance factors, reduce the release of pro-inflammatory cytokines, and reduce the severity of chemotherapy-related leukopenia, thrombocytopenia, and mortality.
Article
Multidisciplinary Sciences
Jiayu Wang, Tao Sun, Quchang Ouyang, Yiqun Han, Binghe Xu
Summary: This study investigated the safety and preliminary efficacy of TQB2450, an anti-PD-L1 antibody, combined with anlotinib, a multi-kinase inhibitor, in advanced TNBC. The results showed that the combination therapy of TQB2450 and anlotinib as a chemotherapy-free treatment demonstrated promising efficacy with a manageable safety profile for previously treated advanced TNBC patients.
Editorial Material
Cell Biology
Mingang Hao, Syn Kok Yeo, Jun-Lin Guan
Summary: Autophagy inhibition can effectively prevent the occurrence of ERBB2-driven breast tumors, with stronger effects than previous studies using other models. Autophagy inhibition disrupts intracellular trafficking of ERBB2 and triggers its release via extracellular vesicles.
Article
Radiology, Nuclear Medicine & Medical Imaging
Sebastian Werner, Bernhard Krauss, Marius Horger
Summary: The study revealed that systemic lung cancer treatment-induced changes in bone marrow attenuation were not yet investigated, showing a significant drop in bone marrow attenuation regardless of the degree of toxicity or myelosuppression. There was no significant tendency towards a subsequent elevation in bone marrow attenuation.
QUANTITATIVE IMAGING IN MEDICINE AND SURGERY
(2022)
Article
Multidisciplinary Sciences
Ana Luisa Correia, Joao C. Guimaraes, Priska Auf Der Maur, Duvini De Silva, Marcel P. Trefny, Ryoko Okamoto, Sandro Bruno, Alexander Schmidt, Kirsten Mertz, Katrin Volkmann, Luigi Terracciano, Alfred Zippelius, Marcus Vetter, Christian Kurzeder, Walter Paul Weber, Mohamed Bentires-Alj
Summary: The study investigates how different tissue-specific microenvironments can either inhibit or support the progression of breast cancer in the liver. It identifies the interplay between natural killer (NK) cells and activated hepatic stellate cells (aHSCs) as a master switch of cancer dormancy, suggesting that therapies aimed at normalizing the NK cell pool may be successful in preventing metastatic outgrowth.
Article
Oncology
Lucia Vigano, Alberta Locatelli, Adele Ulisse, Barbara Galbardi, Matteo Dugo, Diego Tosi, Carlo Tacchetti, Tiziana Daniele, Balazs Gyorffy, Lorenzo Sica, Marina Macchini, Milvia Zambetti, Stefania Zambelli, Giampaolo Bianchini, Luca Gianni
Summary: This study investigates the interplay between ER and HER2 and its impact on the growth and progression of ER-positive breast cancer. It finds that combination therapy can bypass resistance mechanisms and that RTK functional activation may be an alternative survival pathway in ER+/HER2(low) tumors.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Xavier Pivot, M. A. Georgievich, Volodymyr Shamrai, Giorgi Dzagnidze, Hwoei Fen Soo Hoo, Viriya Kaewkangsadan, Fausto Petrelli, Cristian Villanueva, Lipatov O. Nikolaevich, Jocelyn Hii, Jamie Kim, Sumita Pradhan, Litha Jaison, Peggy Feyaerts, Leonard Kaufman, Marie-Paule Derde, Ghislain M. C. Bonamy, Filip Deforce, David G. Cox
Summary: This randomized clinical trial compared the efficacy of HD201 and referent trastuzumab in treating ERBB2-positive early breast cancer. The results showed that HD201 demonstrated equivalence to referent trastuzumab in terms of achieving total pathological complete response (tpCR), with similar safety profiles.
Article
Biochemistry & Molecular Biology
Sunil Kumar Patnaik, Selvaraj Ayyamperumal, Dhananjay Jade, Nagarjuna Palathoti, Krishna Swaroop Akey, Srikanth Jupudi, Michael A. Harrison, Sreenivasan Ponnambalam, M. J. Nanjan, M. J. N. Chandrasekar
Summary: Human epidermal growth factor receptors (EGFR), including ErbB1/HER1, ErbB2/HER2/neu, ErbB3/HER3, and ErbB4/HER4, are overexpressed in various cancers and have important roles in cancer progression and therapy resistance. This study identified five potential dual inhibitors against ErbB1 and ErbB2 through virtual high throughput screening of natural peptides and in silico evaluations, suggesting their potential for cancer treatment.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2023)
Article
Oncology
Seyed Pairawan, Ming Zhao, Erkan Yuca, Allen Annis, Kurt Evans, David Sutton, Luis Carvajal, Jian-Guo Ren, Solimar Santiago, Vincent Guerlavais, Argun Akcakanat, Coya Tapia, Fei Yang, Priya Subash Chandra Bose, Xiaofeng Zheng, Ecaterina Ileana Dumbrava, Manuel Aivado, Funda Meric-Bernstam
Summary: MDM2/MDMX proteins are often elevated in ER+ breast cancer. ALRN-6924 showed significant activity in WT-TP53 cancer cell lines, particularly in combination with chemotherapeutic agents such as paclitaxel. The combination of ALRN-6924 with chemotherapy demonstrated enhanced antitumor efficacy and increased p21 expression in ER+ breast cancer models.
BREAST CANCER RESEARCH
(2021)
Article
Oncology
Kurt W. Evans, Erkan Yuca, Stephen S. Scott, Ming Zhao, Natalia Paez Arango, Christian X. Cruz Pico, Turcin Saridogan, Maryam Shariati, Caleb A. Class, Christopher A. Bristow, Christopher P. Vellano, Xiaofeng Zheng, Ana Maria Gonzalez-Angulo, Xiaoping Su, Coya Tapia, Ken Chen, Argun Akcakanat, Bora Lim, Debu Tripathy, Timothy A. Yap, Maria Emilia Di Francesco, Giulio F. Draetta, Philip Jones, Timothy P. Heffernan, Joseph R. Marszalek, Funda Meric-Bernstam
Summary: Oxidative phosphorylation is a metabolic vulnerability in triple-negative breast cancer, and inhibiting it with IACS-10759 may enhance efficacy of multiple targeted therapies.
Article
Medicine, Research & Experimental
Yanli Bi, Xiaoyu Chen, Bajin Wei, Linchen Wang, Longyuan Gong, Haomin Li, Xiufang Xiong, Yongchao Zhao
Summary: DEPTOR interacts with and stabilizes ErbB2, promoting proliferation and survival of ErbB2-positive breast cancer cells. Overexpression of DEPTOR is correlated with poorer patient survival, and the membrane localization of DEPTOR may contribute to the oncogenic characteristics of ErbB2.
Article
Biochemistry & Molecular Biology
Mohamamdhossein Hassanshahi, Yu-Wen Su, Chia-Ming Fan, Samira Khabbazi, Alireza Hassanshahi, Cory J. Xian
JOURNAL OF CELLULAR BIOCHEMISTRY
(2019)
Article
Biochemistry & Molecular Biology
Jinlin Cai, Liang Huang, Jun Huang, Liang Kang, Hongcheng Lin, Pinzhu Huang, Peixuan Zhu, Jianping Wang, Jianghui Dong, Liping Wang, Cory J. Xian
JOURNAL OF CELLULAR BIOCHEMISTRY
(2019)
Article
Cell Biology
Yuan-Yuan Wang, Xiu-Ying Pu, Wen-Gui Shi, Qing-Qing Fang, Xin-Ru Chen, Hui-Rong Xi, Yu-Hai Gao, Jian Zhou, Cory J. Xian, Ke-Ming Chen
JOURNAL OF CELLULAR PHYSIOLOGY
(2019)
Article
Endocrinology & Metabolism
Qian Tang, Yu-Wen Su, Chia-Ming Fan, Rosa Chung, Mohammadhossein Hassanshahi, Yaser Peymanfar, Cory J. Xian
JOURNAL OF BONE AND MINERAL RESEARCH
(2019)
Review
Cell Biology
Alireza Hassanshahi, Mohammadhossein Hassanshahi, Samira Khabbazi, Zahra Hosseini-Khah, Yaser Peymanfar, Saman Ghalamkari, Yu-Wen Su, Cory J. Xian
JOURNAL OF CELLULAR PHYSIOLOGY
(2019)
Review
Cell Biology
Mohammadhossein Hassanshahi, Samira Khabbazi, Yaser Peymanfar, Alireza Hassanshahi, Zahra Hosseini-Khah, Yu-Wen Su, Cory J. Xian
JOURNAL OF CELLULAR PHYSIOLOGY
(2019)
Review
Pharmacology & Pharmacy
Samira Khabbazi, Mohammadhossein Hassanshahi, Alireza Hassanshahi, Yaser Peymanfar, Yu-Wen Su, Cory J. Xian
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
(2019)
Article
Cell Biology
Mohammadhossein Hassanshahi, Yu-Wen Su, Samira Khabbazi, Chia-Ming Fan, Qian Tang, Xuesen Wen, Jian Fan, Ke-Ming Chen, Cory J. Xian
JOURNAL OF CELLULAR PHYSIOLOGY
(2019)
Article
Cell Biology
Yu-Wen Su, Jian Fan, Chia-Ming Fan, Yaser Peymanfar, Ya-Li Zhang, Cory J. Xian
Summary: The intensive use of MTX and/or DEX in treating childhood malignancies can lead to chondrocyte apoptosis and growth plate dysfunction, causing bone growth impairments. This study found that treatment with MTX and/or DEX induced significant cell apoptosis and stimulated osteoclastic migration and formation, potentially linked molecularly by CXCL12 induction. The findings contribute to a better understanding of the mechanisms behind bone growth impairments following MTX and/or DEX therapy.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Article
Cell Biology
Yali Zhang, Liang Liu, Katherine A. Pillman, John Hayball, Yu-Wen Su, Cory J. Xian
Summary: The study confirmed the bone/fat switch post-MTX treatment, identified miRNAs such as miR-6315 associated with bone and marrow fat formation, and constructed a comprehensive miRNA-mRNA regulatory network for potential pathogenesis/prognosis of MTX-related bone loss and marrow adiposity.
JOURNAL OF CELLULAR PHYSIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Ya-Li Zhang, Liang Liu, Yu-Wen Su, Cory J. Xian
Summary: The study shows that miR-542-3p is downregulated during bone loss and marrow adiposity induced by MTX treatment in childhood malignancies. Through target prediction and luciferase assays, it was confirmed that miR-542-3p targets sFRP-1 and Smurf2 to regulate osteogenesis and adipogenesis balance. Additionally, further analyses revealed that miR-542-3p influences Wnt/beta-catenin and TGF-beta signaling pathways in osteoblastic cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Cell Biology
Yaser Peymanfar, Yu-Wen Su, Cory J. Xian
Summary: Childhood cancer methotrexate (MTX) chemotherapy often leads to bone growth impairments, bone loss, and increased risks of fractures. This study found that MTX treatment caused decreased trabecular bone volume, increased osteoclast formation and activity, and decreased osteogenesis from bone marrow stromal cells. Notch2 signaling played a critical role in mediating MTX-induced bone loss and bone marrow adiposity, and targeting Notch2 could be a potential therapeutic option.
Article
Cell Biology
Yaser Peymanfar, Yu-Wen Su, Mohammadhossein Hassanshahi, Cory J. Xian
Summary: This study reveals that intensive cancer chemotherapy with methotrexate (MTX) can lead to dysfunction and damage of bone vasculature. The activation of Notch2 signaling pathway and increased production of inflammatory cytokine TNF alpha are associated with the impairment of micro-vasculature caused by MTX treatment. Blockade of Notch2 can alleviate the adverse effects on bone micro-vasculature and protect endothelial cell functions from MTX damage.
Article
Oncology
Yu-Wen Su, Alice M. C. Lee, Xukang Xu, Belinda Hua, Heather Tapp, Xue-Sen Wen, Cory J. Xian
Summary: Vitamin D deficiency is common in childhood cancer patients and survivors after chemotherapy, and more research is needed to explore the reasons behind it and the effectiveness of vitamin D supplementation in preventing chemotherapy-induced bone loss. This study used a rat model to show that methotrexate chemotherapy causes vitamin D deficiency, bone loss, and altered intestinal vitamin D metabolism, and that vitamin D supplementation can attenuate the bone loss.